On March 6, 2024, GSK plc's subsidiary ViiV Healthcare presented interim data at CROI showing that their long-acting injectable HIV treatment, Cabenuva, is more effective than daily oral therapy for individuals struggling with adherence, with a regimen failure rate of 24.1% compared to 38.5% for oral therapy.